📌 Key Takeaways
- Topic: Buying Silica on Alibaba: How to Verify Suppliers and Avoid Common Risks
- Keywords: silica thixotropic agent
- Published: 2026-11-20 13:36:08
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
What Is Green Tire Silica? Role in Low Rolling Resistance and Fuel-Efficient Tires
- Silica for Coatings: Types, Functions and How to Choose the Right Grade
- Silica as a Desiccant: Moisture Capacity, Types and Uses
- Vartuli, J. et al. Impact of surfactant/silica molar ratios on the formation of mesoporous molecular sieves: inorganic mimicry of surfactant liquid-crystal phases and mechanistic implications. Chem. Mater. 6, 2317-2326 (1994). Article CAS Google Scholar
- How to Modify Nano Silica: Surface Modification Methods and Silane Selection
- For carbon-based nanomaterials, they can serve as photothermal agents for photothermal antibacterial and photothermal tumor ablation due to their broad-spectrum light-absorption properties. 235, 236, 237, 238 Nevertheless, the disadvantages such as poor solubility and negative material-biological interface interactions limit their further applications. 239, 240 To address this issue, MSNs-coated carbon-based nanomaterials have been produced. Such-constructed nanocomposites not only improve the surface interface properties of carbon-based materials, but also combine the perks of two different drug carriers, including the enhanced water solubility and dispersibility, easier surface functionalization properties and higher drug loading and delivery performance. 219, 241 Another problematic facet of carbon-based materials is that their in vivo biodegradability is difficult to manipulate, which may bring some potential long-term physiological toxicity issues. 242 In tumor therapy, although NPs smaller than 5.5 nm can typically be cleared from the body by the renal metabolic system, particle sizes too small to be enriched to tumor sites by the enhanced permeability and retention (EPR) influence when performing administration intravenously. 243, 244, 245 For this reason, researchers can use the MSNs with outstanding biodegradable properties to address these issues of carbon-based nanomaterials. 229 A recent study demonstrated that by coating a carbon layer on the surface of dendritic degradable MSNs, accelerated degradation of MSNs and collapse of the surface carbon layer could be observed with NIR irradiation. This carbon-silica nanocomposite was swiftly cleared from the body after completion of a synergistic PTT and PDT. 229
- Silica vs Silicone: Key Differences in Structure, Properties and Uses
- Clinical translation
What Is Silica Powder? Types, Particle Sizes, Grades and Common Applications
What is silica (SiO₂)?
silica manufacturers list Feliczak-Guzik, A., Szczyglewska, P., Jaroniec, M. & Nowak, I. Ruthenium-containing SBA-12 catalysts for anisole hydrodeoxygenation. Catal. Today 354, 67-76 (2020). Article CAS Google Scholar
What is the difference between fumed silica and precipitated silica?
silica supplier Indonesia Chen, B. & Wang, F. Emerging frontiers of upconversion nanoparticles. Trends Chem. 2, 427-439 (2020). Article Google Scholar
What drives silica raw material prices?
precipitated silica manufacturer Jana, D. & Zhao, Y. Tactics for enhancing cancer chemodynamic therapy performance. Exploration 2, 20210238 (2022). Piece PubMed Central PubMed Google Scholar
Cite this article: Silica Raw Materials News. "Amorphous vs Crystalline Silica: Structure, Safety and Uses Compared
." Published 2026-11-20 13:36:08.
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.